76,525 Shares in Becton, Dickinson and Company $BDX Bought by Caisse DE Depot ET Placement DU Quebec

Key Points

• Caisse DE Depot ET Placement DU Quebec purchased 76,525 shares of Becton, Dickinson and Company (NYSE: BDX), valued at approximately $17.5 million, highlighting institutional interest in the medical instruments supplier.
• Insider transactions included Director Claire Fraser selling 863 shares for $165,954.90, reducing her ownership by 3.59%, while EVP Michael David Garrison sold 1,185 shares, a 19.52% decrease in his holdings.
• Following quarterly earnings that exceeded analyst expectations, the company set its FY 2025 EPS guidance at 14.300-14.450, while announcing a quarterly dividend of $1.04 per share.

Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 76,525 shares of the medical instruments supplier's stock, valued at approximately $17,529,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. Hara Capital LLC raised its position in shares of Becton, Dickinson and Company by 26.4% in the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 70 shares in the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Becton, Dickinson and Company by 5.1% in the 4th quarter. Integrated Wealth Concepts LLC now owns 4,973 shares of the medical instruments supplier's stock valued at $1,128,000 after buying an additional 243 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 3.6% in the 4th quarter. AQR Capital Management LLC now owns 408,097 shares of the medical instruments supplier's stock valued at $92,585,000 after buying an additional 14,258 shares in the last quarter. Finally, Voleon Capital Management LP acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $1,583,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Up 0.8%

Shares of Becton, Dickinson and Company stock traded up $1.59 during midday trading on Monday, reaching $192.84. The company had a trading volume of 1,329,461 shares, compared to its average volume of 2,422,682. The stock has a fifty day moving average price of $183.07 and a 200 day moving average price of $193.83. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market cap of $55.27 billion, a PE ratio of 34.68, a P/E/G ratio of 1.44 and a beta of 0.27. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the firm earned $3.50 earnings per share. The firm's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 863 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on BDX. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.